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ABSTRACT 
 
Background: Retroviruses of human T-lymphotropic viruses (HTLV-1 and HTLV-2) have been demonstrated to be 
endemic in the north-eastern region of Iran. This study was aimed to determine the HTLV-1 and HTLV-2 
prevalence among healthy individuals in Neyshabur City during 2010-2014. Methods: A total of 8054 blood 
samples were collected from healthy participants in Neyshabur, North-Eastern Iran. The blood samples were 
screened for the presence of specific antibodies against HTLV-1 and HTLV-2 by using ELISA according to the 
manufacturer’s instructions. Results: The overall seropositivity rate for HTLV-1 and HTLV-2 was found to be 6.55% 
(528 out of 8054) among participants. Conclusion: Both HTLV-1 and HTLV-2 were demonstrated to be at a high 
rate in healthy individuals. However, a smaller number of asymptomatic carriers were found in this study, as 
compared to those identified in previous investigations in the city. DOI: 10.6091/.21.1.57  
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INTRODUCTION 
 
uman T-lymphotropic viruses (HTLV-1 and 
HTLV-2), classified in the retroviridae family, 
are among the first identified species
[1-3]
. 
HTLV-1 and HTLV-2 are widespread all over the 
world and are endemic in different areas, including 
North-Eastern Iran
[4-6]
. According to a previous study, 
the rate of HTLV-1 infection has been reported to be 
less than 0.26% in Mashhad, North-Eastern Iran, while 
it does not exceed 0.34% in other areas of the 
country
[7]
. The prevalence of HTLV-1 infection in 
other countries such as Turkmenistan, Brazil, Spain, 
Korea and Japan was found to be 0.007%
[8]
, 1.9%
[9]
, 
0.001%
[10]
, 0.27%
[11]
, and 0.12%
[12]
, respectively.  
HTLV-1- and HTLV-2-infected carriers remain 
asymptomatic for a long time, serving as a potential 
source for the transmission of the disease
[13]
. The aim 
of this investigation was to determine the prevalence of 
HTLV-1 and HTLV-2 among healthy individuals in 
Neyshabur, North-Eastern Iran, during 2010-2014.  
 
 
MATERIALS AND METHODS 
 
Study population 
A total of 8054 healthy individuals from Neyshabur, 
North-Eastern Iran, were included in this study. Serum 
samples (5 ml) were prepared from the individuals and 
stored at -20°C until the ELISA test.  
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                           Table 1. Age- and sex-based distribution of individuals and overall HTLV-positive cases  
 
Variable No. 
Positive cases 
 (%) 
Odd Ratio  
(OR) 
OR  
(95%CI) 
P  
value 
Age (year)      
0-19 429 13(3.03) Baseline  <0.0001 
20-29 2556 49(1.92) 0.625 0.336-1.163 
30-39 2018 88(4.36) 1.459 0.807-2.637 
≥40 3051 377(12.36) 4.512 2.571-7.918 
      
Gender       
Male 1565 130(8.31) 
1.386 1.128-1.704 0.002 
Female 6489 398(6.13) 
 
 
Serological assays and confirmation tests  
Serum samples were screened for the presence of 
specific antibodies against HTLV-1 and HTLV-2 by 
ELISA (Dia.Pro Diagnostic Bioprobes, Italy) 
according to the manufacturer’s instructions
[14]
.  
 
Statistical analysis 
The SPSS software (version 20) was employed to 
analyze all data using chi-square and t-test. A P<0.05 
was considered to be statistically significant.  
 
 
RESULTS AND DISCUSSION 
 
Of 8054 healthy individuals participated in the study, 
1565 (19.4%) and 6489 (80.6%) were males and 
females, respectively. As shown in Table 1, the mean 
age of males and females was 46±3 and 51±3 years, 
respectively. The positivity of the samples was 6.55% 
(528 out of 8054), including 3.6% for HTLV-1 and 
1.4% for HTLV-2. Table 2 indicates the total 
prevalence of HTLV-1 and HTLV- 2 in each year.  
Previous studies have revealed that HTLV-1 is 
endemic in North-Eastern Iran
[15]
. Another study in 
Neyshabur has indicated that the prevalence of HTLV-
1 is 7.2% (35 out of 483)
[16]
. However, the rate of 
HTLV-1 seropositivity has gradually decreased from 
1.97% in 1996 to 0.26% in 2014
[17-19]
 in other regions 
of North-Eastern Iran. Similarly, the results of the 
present study demonstrated that the prevalence of 
HTLV-1 has decreased in Neyshabur from 2010 to 
2014. In a survey carried out in Mashhad in 2012, the 
rate of HTLV-1 was detected to be 0.47%
[20]
. The 
seroprevalence of HTLV-1 did not exceed 0.19% in a 
study conducted by Safabakhsh et al.
[7]
. It seems that 
the reduction in HTLV-1 rate is mainly due to the 
improvement of blood donor selection and increased 
awareness among blood donors. However, in a study 
performed by Rafatpanah et al.
[21]
 in Mashhad, it was 
revealed that the prevalence of HTLV-1 is 20% (10 
positive samples), although no evidence of HTLV-2 
infection was found among immuneblotted samples 
and nested PCR.  
In the current study, over 3% of healthy individuals 
were positive for HTLV-1 in all five years. To the best 
of our knowledge, there is a small number of published 
data regarding HTLV-2 prevalence in Iran. Also, a 
lower rate of positive HTLV-1 infection was identified 
in the present investigation, when compared to  
a   previously  study   in   Neyshabur
[22]
.   This   finding  
 
 
                                  
                                        Table 2. The annual prevalence of HTLV-1 and HTLV-2 investigated in this study 
 
 
Total percentage HTLV-2 (%) HTLV-1 (%) Number Year 
3.01 ND 3.01 
Positive: 58 
2014 
Total:  1350 
     
4.11 ND 4.11 
Positive: 94 
2013 
Total:  2337 
     
5.12 ND 5.12 
Positive: 115 
2012 
Total:  2188 
     
5.12 ND 5.13 
Positive: 117 
2011 
Total:  2057 
     
5.74 ND 5.74 
Positive: 122 
2010 
Total:  1789 
 
                                  ND, not determined 
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highlights that Neyshabur is a major endemic region 
for HTLV-1. In addition, a higher prevalence of 
HTLV-1 was found in the age groups over 40 years, 
suggesting that there is a relationship between HTLVs 
and the age of individuals. 
In the present study, a high rate of HTLV-1 among 
serum samples was detected using the ELISA test 
among healthy individuals in Neyshabur city during 
2010-2014. The results from this study emphasize that 
HTLV is still an important endemic disease in 
Neyshabur. More importantly, the prevalence of 
HTLV-1 in Neyshabur was detected to be higher than 
other city (Mashhad) in all duration of this study, 
though being in a decreasing status compared to the 
previous reports.  
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